Online supplement Table 1s: Respiratory Adverse Events, Asthma (multiple symptoms) AEs, and Hospitalizations In the 5 Years Following BT

	Proportion of BT Subjects Experiencing One or More Events (%)			Event Rates (Events/Subject/Year)		
	Respiratory Adverse Events[1]	Asthma (multiple symptoms) Adverse Events[2]	Hospitalizations for Respiratory Symptoms	Respiratory Adverse Events[1]	Asthma (multiple symptoms) Adverse Events[2]	Hospitalizations for Respiratory Symptoms
12 Months before BT (n=190)	NA*	NA*	4.2 [1.4, 7.1]	NA*	NA*	0.053 [0.04, 0.08]
Year 1 (n=181)	72.9 [66.5, 79.4]	28.7 [22.1, 35.3]	3.3 [0.7, 5.9]	2.02 [1.764, 2.318]	0.481 [0.379, 0.609]	0.04 [0.025, 0.060]
Year 2 (n=165)	58.8 [51.3, 66.3]	27.9 [21.0, 34.7]	4.2 [1.2, 7.3]	1.22 [1.013, 1.465]	0.461 [0.357, 0.594]	0.061 [0.042, 0.087]
Year 3 (n=162)	58.0 [50.4, 65.6]	29.6 [22.6, 36.7]	6.2 [2.5, 9.9]	1.25 [1.037, 1.499]	0.506 [0.396, 0.646]	0.068 [0.048, 0.096]
Year 4 (n=159)	54.7 [47.0, 62.5]	31.4 [24.2, 38.7]	5.7 [2.1, 9.3]	1.18 [0.971, 1.424]	0.503 [0.393, 0.644]	0.076 [0.054, 0.105]
Year 5 (n=162)	47.5 [39.8, 55.2]	24.7 [18.1, 31.3]	1.9 [0.0, 3.9]	0.78 [0.616, 0.982]	0.321 [0.236, 0.436]	0.025 [0.014, 0.044]
Average over 5 years	**58.7 [53.4, 63.8]**	**28.4 [23.7, 33.6]**	**3.9 [2.3, 6.6]**	**1.30 [1.149, 1.481]**	**0.45 [0.374, 0.554]**	**0.053 [0.038, 0.073]**

Values are point estimates and [95% CI]. Year 1 is 365 days after the treatment period (365 days after 6 weeks after last bronchoscopy).

*: Adverse events were not collected for the 12 month period before BT.

[1]: Respiratory adverse events are any and all events related to the respiratory system.

[2]: Asthma (multiple symptoms) adverse events represent two or more asthma symptoms such as wheeze, cough, dyspnea, mucus production etc. occurring at the same time.

There were a total of 44 respiratory hospitalizations over 5 years in 23 subjects (7 hospitalizations in 6 subjects in Year 1, 10 hospitalizations in 7 subjects in Year 2, 11 hospitalizations in 10 subjects in Year 3, 12 hospitalizations in 9 subjects in Year 4, and 4 hospitalizations in 3 subjects in Year 5). Three subjects accounted for 20 of the 44 total hospitalizations (45.5%) spread out over 5 years.

Online supplement Table 2s: Event Rates: Responders versus Non-Responders (Events/Subject/Year)

	Event Rates (Events/Subject/Year)					
	Year 1	Year 2	Year 3	Year 4	Year5	Mean Year2 to Year5
Severe Exacerbations						
Responders	0.425	0.288	0.458	0.504	0.313	0.389
Non-Responders	0.743	0.879	0.936	0.800	0.290	0.720
Respiratory AEs[1]						
Responders	1.849	1.061	1.176	1.001	0.718	1.012
Non-Responders	2.743	1.849	1.548	1.500	1.032	1.487
Asthma (Multiple Symptoms) AEs[2]						
Responders	0.397	0.364	0.420	0.434	0.282	0.376
Non-Responders	0.829	0.849	0.871	0.800	0.484	0.745
ER Visits for Respiratory Symptoms						
Responders	0.062	0.038	0.107	0.070	0.061	0.068
Non-Responders	0.114	0.273	0.258	0.200	0.097	0.214
Hospitalizations for Respiratory Symptoms						
Responders	0.021	0.046	0.061	0.085	0.015	0.051
Non-Responders	0.114	0.121	0.097	0.033	0.065	0.079

Responders: Subjects with AQLQ score change from Baseline to Year 1 of ≥0.5
(n Year 1 =146; n Year 2 =132, n Year 3 =131, n Year 4 =129, n Year 5=131).

Non-Responders: Subjects with AQLQ score change from Baseline to Year 1 of <0.5
(n Year 1 =35; n Year 2 =33, n Year 3 =31, n Year 4 =30, n Year 5=31).

[1]: Respiratory adverse events are any and all events related to the respiratory system.
[2]: Asthma (multiple symptoms) adverse events represent two or more asthma symptoms such as wheeze, cough, dyspnea, mucus production etc. occurring at the same time.

Online Supplement Figure 1

***Legend for Online Supplement Figure 1*:** Annualized severe exacerbation rates (top panel) and emergency room visit rates (bottom panel) in the AIR2 Trial over the 5 year evaluation periods. The data for Year 1 in these figures for both the Sham (white bars) and BT groups (blue bars) are standardized to 52 weeks. The solid bars in both graphs represent the Post-Treatment Period, and the hashed bars represent the Treatment Period.